Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
Panelists discuss recent data updates on transplant-ineligible and deferred newly diagnosed multiple myeloma (NDMM), including findings from the CEPHEUS and IMROZ studies, and explore the clinical significance of minimal residual disease negativity as a prognostic and actionable factor in treatment decision-making for NDMM.
Video content above is prompted by the following:
- Please comment on recent data updates for transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM):
- CEPHEUS study, SubQ Dara-VRd vs VRd in transplant-ineligible NDMM
- IMROZ study, Isa-VRd vs VRd in TIE/deferred NDMM
- What is the clinical significance of minimal residual disease (MRD) negativity as a clinical outcome? How do you interpret and integrate MRD negativity into your clinical decision-making? Beyond its prognostic value, what actionable insights does MRD provide in guiding treatment strategies and patient management?
- Please highlight key insights from MRD analyses in NDMM presented at ASH 2024.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
